ESSA Pharma Inc. has announced significant developments in its restructuring process, including a return of capital distribution worth $80 million to its shareholders. This move is part of the company's winding-up process following a transaction with XenoTherapeutics, Inc., a non-profit biotechnology company, which will acquire all of ESSA's outstanding common shares. The distribution is set to be paid on August 22, 2025, with shareholders receiving roughly $1.69 per share. Due to the distribution exceeding 25% of the share price, Nasdaq has implemented a "due bill" trading period from August 19 to August 25, 2025. During this time, shares traded will include the right to the distribution, impacting sellers who will not receive the distribution if they sell during this period. Shareholders and potential buyers are advised to consult with their brokers to understand the implications of these trading procedures.